The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer

Publisher： Karger

E-ISSN： 2296-5262|25|6|511-518

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.25, Iss.6, 2003-01, pp. : 511-518

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments

By  

Current Signal Transduction Therapy, Vol. 4, Iss. 2, 2009-05 ,pp. : 130-143

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the ERK signaling pathway in cancer therapy

By Kohno Michiaki   Pouyssegur Jacques  

Annals of Medicine, Vol. 38, Iss. 3, 2006-05 ,pp. : 200-211

Informa Healthcare

Access to resources Recommend Favorite

Cilostazol Prevents Atrial Structural Remodeling through the MEK/ERK Pathway in a Canine Model of Atrial Tachycardia

By  

Cardiology, Vol. 135, Iss. 4, 2016-08 ,pp. : 240-248

Karger

Access to resources Recommend Favorite

Hydrogen-rich saline attenuates vascular smooth muscle cell proliferation and neointimal hyperplasia by inhibiting reactive oxygen species production and inactivating the Ras-ERK1/2-MEK1/2 and Akt pathways

By            

International Journal of Molecular Medicine, Vol. 31, Iss. 3, 2013-01 ,pp. : 597-606

Spandidos Publications

Access to resources Recommend Favorite

Efficacy of Triplet Combination Chemotherapy with Oxaliplatin, Irinotecan and Capecitabine (OCX) in Metastatic Colorectal Cancer in Relation to RAS/RAF Mutation Status: Results of a Retrospective Analysis

By  

Oncology Research and Treatment, Vol. 37, Iss. 11, 2014-10 ,pp. : 646-652

Karger

Access to resources Recommend Favorite